In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $25.81 in the prior trading day, Zymeworks BC Inc (NASDAQ: ZYME) closed at $25.87, up 0.25%. In other words, the price has increased by $0.25 from its previous closing price. On the day, 0.7 million shares were traded. ZYME stock price reached its highest trading level at $26.18 during the session, while it also had its lowest trading level at $25.45.
Ratios:
Our goal is to gain a better understanding of ZYME by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In the most recent recommendation for this company, Citizens JMP on December 03, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $32.
H.C. Wainwright Upgraded its Neutral to Buy on October 14, 2025, while the target price for the stock was maintained at $26.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 24 ’25 when Derek John Michael Miller bought 118,000 shares for $23.82 per share.
Neil Gallagher bought 105,000 shares of ZYME for $2,501,100 on Nov 21 ’25. On May 15 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 49,502 shares for $11.43 each. As a result, the insider paid 565,847 and bolstered with 17,877,989 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1959274496 and an Enterprise Value of 1702992128. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.51 while its Price-to-Book (P/B) ratio in mrq is 6.12. Its current Enterprise Value per Revenue stands at 12.663 whereas that against EBITDA is -27.93.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.30, which has changed by 1.0447702 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $28.49, while it has fallen to a 52-week low of $9.03. The 50-Day Moving Average of the stock is 25.98%, while the 200-Day Moving Average is calculated to be 73.45%.
Shares Statistics:
The stock has traded on average 1.13M shares per day over the past 3-months and 960870 shares per day over the last 10 days, according to various share statistics. A total of 75.14M shares are outstanding, with a floating share count of 72.92M. Insiders hold about 3.30% of the company’s shares, while institutions hold 99.50% stake in the company. Shares short for ZYME as of 1764288000 were 5609170 with a Short Ratio of 4.97, compared to 1761868800 on 7531090. Therefore, it implies a Short% of Shares Outstanding of 5609170 and a Short% of Float of 10.9799996.
Earnings Estimates
Investors are keenly observing as 10.0 analysts analyze and rate. The current performance of Zymeworks BC Inc (ZYME) in the stock market.The consensus estimate for the next quarter is -$0.1, with high estimates of $0.55 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.13 and -$1.25 for the fiscal current year, implying an average EPS of -$0.88. EPS for the following year is $0.25, with 11.0 analysts recommending between $3.76 and -$1.52.
Revenue Estimates
9 analysts predict $21.21M in revenue for. The current quarter. It ranges from a high estimate of $59M to a low estimate of $1.2M. As of. The current estimate, Zymeworks BC Inc’s year-ago sales were $31.03MFor the next quarter, 9 analysts are estimating revenue of $22.6M. There is a high estimate of $29.8M for the next quarter, whereas the lowest estimate is $14.58M.
A total of 11 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $162.09M, while the lowest revenue estimate was $104.5M, resulting in an average revenue estimate of $124.33M. In the same quarter a year ago, actual revenue was $76.3MBased on 11 analysts’ estimates, the company’s revenue will be $246.12M in the next fiscal year. The high estimate is $502.1M and the low estimate is $96.08M.
